Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274890 | 1.00 | SLC22A6 (0.31) | SLC22A6GRIA1 | |
| SCHEMBL29468542 | 0.80 | ENPEP (0.30) | — | |
| SCHEMBL475100 | 0.78 | — | — | |
| SCHEMBL19091152 | 0.70 | CA12 (0.34) | — | |
| SCHEMBL8747569 | 0.70 | — | — | |
| SCHEMBL5399745 | 0.69 | — | — | |
| SCHEMBL3381831 | 0.69 | — | — | |
| SCHEMBL196076 | 0.69 | — | — | |
| SCHEMBL27084645 | 0.69 | SLC22A6 (0.41) | SLC22A6GRIA1 | |
| SCHEMBL14179654 | 0.69 | SLC22A6 (0.36) | SLC22A6GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049922-A1 | PHARMACEUTICAL COMPOSITION COMPRISING P-BORONOPHENYLALANINE | TENBORON OY (FI) | 2025-02-13 | — | — | US | claimed |
| US-20240398696-A1 | DELIVERY OBJECTS SUITABLE FOR NEEDLE-FREE INJECTION EQUIPMENTS | CHUANG PING YEN (TW) | 2024-12-05 | — | — | US | claimed |
| EP-4448010-A1 | PHARMACEUTICAL COMPOSITION COMPRISING P-BORONOPHENYLALANINE | Tenboron OY (FI) | 2024-10-23 | — | — | EP | claimed |
| CN-118317790-A | Pharmaceutical composition comprising p-borophenylalanine | 腾博龙公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2023111396-A1 | PHARMACEUTICAL COMPOSITION COMPRISING P-BORONOPHENYLALANINE | TENBORON OY (FI) | 2023-06-22 | — | — | WO | claimed |
| US-20210299265-A1 | EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2021-09-30 | — | — | US | claimed |
| EP-1869065-A2 | A METHOD OF WEAK PARTITIONING CHROMATOGRAPHY | Wyeth a Corporation of the State of Delaware (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006099308-A2 | A METHOD OF WEAK PARTITIONING CHROMATOGRAPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-0717645-B1 | REDUCTION OF SKIN IRRITATION AND RESISTANCE DURING ELECTROTRANSPORT | ALZA CORP (US) | 1998-05-13 | — | — | EP | claimed |
| US-5624415-A | MAINTAINING ANODIC RESERVOIR AT PH ABOVE 4 AND CATHODIC RESERVOIR AT PH BELOW 4 DURING ELECTROTRANSPORT AGENT DELIVERY | ALZA CORPORATION (US) | 1997-04-29 | — | — | US | claimed |
| EP-3310336-B1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACECLIDINE AND MANNITOL FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4563162-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4552651-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-1993024659-A1 | METHODS AND PHARMACEUTICAL KITS USEFUL FOR DETECTING MICROORGANISMS ASSOCIATED WITH VAGINAL INFECTIONS | MICROPROBE CORPORATION (US) | 1993-12-09 | — | — | WO | disclosed |
| US-5254801-A | Inducing male sterility for hybrid seed production, cell ablation, counter-negative selection; genetic engineering | MONSANTO COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0458971-A1 | INOSINE GUANOSINE KINASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-12-04 | — | — | EP | disclosed |
| EP-0108919-A2 | Process for producing T cell-activating factor | Okai, Yasuji (JP) | 1984-05-23 | — | — | EP | disclosed |
| US-4139440-A | Electrofocusing in buffers | GOVERNMENT OF THE UNITED STATES (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | CHRM2, ADRB2, CHRM3 | SLC22A6 2427/4885GRIA1 2030/4885 |
| US-20210299265-A1 | EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES | EPCAM, CD47, CKAP4 | SLC22A6 968/4885GRIA1 2971/4885 |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | PDE6C, PDE6A, PDE6B | SLC22A6 2330/4885GRIA1 4234/4885 |
| US-20250049922-A1 | PHARMACEUTICAL COMPOSITION COMPRISING P-BORONOPHENYLALANINE | PAH, UGT2B7, UGT2B17 | SLC22A6 125/4885GRIA1 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.